The cost of a popular Vertex Pharmaceuticals therapy could be contributing to cystic fibrosis (CF) treatment disparities around the world, researchers argued in a recent paper. Just 12% of some ...
The expanded approval was based on clinical and/or in vitro data demonstrating responsiveness across 564 variants for Alyftrek and 521 variants for Trikafta. The label expansions were granted based on ...
BUFFALO, N.Y. — Nicole Ellis completed her first 5k run in 2020, something that just a short time ago would've seemed almost impossible. "I am currently healthier than I have been in the last ten ...
I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic ...
Credit: Vertex. A new oral granule formulation has been approved and is supplied in morning and evening unit-dose packets. The approval was based on data from a 24-week open-label, two-part phase 3 ...
OMAHA, Nebraska (WPVI) -- A newly-approved drug is bringing hope to many people dealing with cystic fibrosis. CF slowly robs patients of their breathing, choking lungs and other organs with thick ...
COLORADO (KCNC) — Some Coloradans are sounding an alarm after learning a state board is considering capping the price of a life-saving drug. They’re worried the move could cause the manufacturer to ...
Vertex Pharmaceuticals (VRTX) is back in focus after the U.S. Food and Drug Administration expanded use of its cystic ...
Vertex Pharmaceuticals VRTX reported strong second-quarter results driven by the continued robust uptake of its cystic fibrosis triple-combination therapy, Trikafta/Kaftrio. Product revenue of $2.49 ...
Vertex Pharmaceuticals Inc. VRTX announced that the FDA has accepted its supplemental new drug application (sNDA) for the label expansion of its triple combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results